Bayer: licensing agreement with US biotech NextRNA
(CercleFinance.com) - Bayer announced on Wednesday that it has signed a licensing agreement with US biotech NextRNA Therapeutics with the aim of discovering new cancer treatments.
Under the terms of the collaboration, the German pharmaceutical group will use the Boston-based company's long non-coding RNA (lncRNA) technology to develop small molecules for oncology.
Bayer and NextRNA explain that they plan to work together on two programs, one of which is already in preclinical trials at NextRNA.
The second will be chosen by Bayer from a portfolio of candidates pre-selected by NextRNA.
Under the terms of the agreement, NextRNA will receive $547 million, in the form of an upfront payment, milestone payments and research funding, as well as royalties on future sales of drugs that may be brought to market.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Under the terms of the collaboration, the German pharmaceutical group will use the Boston-based company's long non-coding RNA (lncRNA) technology to develop small molecules for oncology.
Bayer and NextRNA explain that they plan to work together on two programs, one of which is already in preclinical trials at NextRNA.
The second will be chosen by Bayer from a portfolio of candidates pre-selected by NextRNA.
Under the terms of the agreement, NextRNA will receive $547 million, in the form of an upfront payment, milestone payments and research funding, as well as royalties on future sales of drugs that may be brought to market.
Copyright (c) 2024 CercleFinance.com. All rights reserved.